Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Jamp K8 Tablet

Canada Type II Ongoing · initiated 2025-03-06

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

L-Theanine 250 mg capsule

Canada Type II Ongoing · initiated 2025-03-06

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Golden State Medical Supply Inc.

US Class II Ongoing · initiated 2025-03-05

Failed Dissolution Specifications

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2025-03-05

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Strides Pharma, Inc.

US Class II Ongoing · initiated 2025-03-05

Presence of foreign substance: Presence of Benzene.

Strides Pharma, Inc.

US Class II Ongoing · initiated 2025-03-05

Presence of foreign substance: Presence of Benzene.

L'Oreal USA

US Class II Ongoing · initiated 2025-03-05

cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of…

L'Oreal USA

US Class II Ongoing · initiated 2025-03-05

cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of…

L'Oreal USA

US Class II Ongoing · initiated 2025-03-05

Chemical Contamination: This recall has been initiated due to detected trace levels of benzene.

Deep Lung Cleanse Capsule

Canada Type III Ongoing · initiated 2025-03-05

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Sodium Acetate Injection USP

Canada Type II Ongoing · initiated 2025-03-05

Labelling. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

Chattem Inc

US Class II Ongoing · initiated 2025-03-04

CGMP Deviations: Nitrosamine Drug Substance Related Issue impurity above the daily acceptable intake limit defined by the Food and Drug Administration.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories

US Class III Terminated · initiated 2025-03-04

Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.

SUN PHARMACEUTICAL INDUSTRIES INC

US Class III Ongoing · initiated 2025-03-04

Cross Contamination

SUN PHARMACEUTICAL INDUSTRIES INC

US Class III Ongoing · initiated 2025-03-04

Cross Contamination

Jamp Itraconazole Oral Solution

Canada Type III Ongoing · initiated 2025-03-03

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Medline Alcohol Prep Pad: 70% Isopropyl Alcohol

Canada Type II Ongoing · initiated 2025-03-03

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Sigan Industries Group Inc.

US Class II Ongoing · initiated 2025-02-28

Chemical Contamination: Presence of benzene

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-02-28

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit